Triple-negative breast cancer is notoriously unresponsive to immunotherapy, and understanding why tumors evade immune destruction remains one of oncology's most pressing puzzles. A newly characterized molecular circuit may help explain this resistance — and, critically, point toward a druggable target that could make checkpoint blockade far more effective.
The research identifies the mitochondrial aspartate/glutamate carrier protein SLC25A13 as a central immunometabolic regulator in TNBC. Elevated SLC25A13 expression correlates with poor prognosis and reduced CD8+ T-cell infiltration in clinical breast cancer datasets. Mechanistically, the protein physically interacts with STAT3, boosting Complex I-linked oxidative phosphorylation and constraining mitochondrial reactive oxygen species. This metabolic reprogramming activates STAT3, which then translocates to the nucleus and transcriptionally upregulates IFI6 — an interferon-stimulated gene that paradoxically protects cancer cells by preserving mitochondrial integrity, limiting lipid peroxidation, and blocking the iron-dependent cell death program known as ferroptosis. The result is a tumor that resists ferroptosis and simultaneously suppresses CD8+ T-cell cytotoxicity, creating a doubly protected immunosuppressive niche. Using structure-guided virtual screening, investigators identified a small-molecule degrader, HY-QS02682823, that triggers lysosomal clearance of SLC25A13, restores ferroptotic vulnerability, reinvigorates CD8+ T-cell function, and enhances anti-PD-1 efficacy in syngeneic mouse TNBC models.
This work is notable for bridging mitochondrial bioenergetics, regulated cell death, and tumor immunology into a single coherent axis — an integration that has been conceptually anticipated but rarely demonstrated mechanistically with this precision. The SLC25A13–STAT3–IFI6 pathway adds meaningful nuance to why ferroptosis induction alone may be insufficient without co-targeting immune evasion machinery. Key limitations include reliance on mouse syngeneic models and cell lines; whether HY-QS02682823 achieves therapeutic pharmacokinetics and tolerability in humans remains untested. Nonetheless, this is a genuinely mechanistic, multi-layered finding that elevates SLC25A13 from an obscure mitochondrial transporter to a plausible combination immunotherapy target worth clinical investigation.